Phaseline

Companies › Dogwood Therapeutics

Dogwood Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Halneuron–Phase 2Chemotherapy Induced Neuropathic PainDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06848348HalneuronPhase 2Chemotherapy Induced Neuropathic PainOncologyDec 2026

From the company's SEC filings

Cash of $5m on 2026-09-30; operating cash outflow about $17m a year; runway about 3 months at that burn, to Jan 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Atossa Therapeutics Curis Processa Pharmaceuticals Moleculin Biotech Aura Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.